Schrödinger (SDGR) Competitors

BridgeBio Pharma (NASDAQ:BBIO) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and institutional ownership.

Which has better earnings and valuation, BBIO or SDGR?

Schrödinger has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Schrödinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$127.42M	49.13	-$535.76M	-$3.53	-9.34
Schrödinger	$230.49M	6.82	$40.72M	-$2.63	-8.19

Does the media favor BBIO or SDGR?

In the previous week, Schrödinger had 4 more articles in the media than BridgeBio Pharma. MarketBeat recorded 16 mentions for Schrödinger and 12 mentions for BridgeBio Pharma. Schrödinger's average media sentiment score of 1.02 beat BridgeBio Pharma's score of 0.80 indicating that Schrödinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrödinger	10 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders hold more shares of BBIO or SDGR?

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 79.1% of Schrödinger shares are held by institutional investors. 18.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 8.6% of Schrödinger shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Do analysts recommend BBIO or SDGR?

BridgeBio Pharma currently has a consensus price target of $57.09, suggesting a potential upside of 73.17%. Schrödinger has a consensus price target of $32.80, suggesting a potential upside of 52.31%. Given BridgeBio Pharma's higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Schrödinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92
Schrödinger	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor BBIO or SDGR?

BridgeBio Pharma received 123 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 72.47% of users gave BridgeBio Pharma an outperform vote while only 58.33% of users gave Schrödinger an outperform vote.

Company	Underperform	Outperform
BridgeBio Pharma	Outperform Votes 179 72.47%	Underperform Votes 68 27.53%
Schrödinger	Outperform Votes 56 58.33%	Underperform Votes 40 41.67%

Which has more risk & volatility, BBIO or SDGR?

BridgeBio Pharma has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500.

Is BBIO or SDGR more profitable?

Schrödinger has a net margin of -91.84% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Schrödinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-241.44%	N/A	-75.69%
Schrödinger	-91.84%	-35.77%	-24.51%

Summary

Schrödinger beats BridgeBio Pharma on 11 of the 19 factors compared between the two stocks.